Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis | Zendy

В. Т. Ивашкин | Zendy; И. В. Маев | Zendy; Chavdar S Pavlov | Zendy; M.V. Mayevskaya | Zendy; А А Самсонов | Zendy; Л. К. Пальгова | Zendy; Kirill M Starostin | Zendy

Open Access

Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis

Author(s) -

В. Т. Ивашкин,

И. В. Маев,

Chavdar S Pavlov,

M.V. Mayevskaya,

А А Самсонов,

Л. К. Пальгова,

Kirill M Starostin

Publication year - 2021

Publication title -

the turkish journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.404

H-Index - 28

eISSN - 2148-5607

pISSN - 1300-4948

DOI - 10.5152/tjg.2021.20294

Subject(s) - medicine , fatty liver , gastroenterology , viral hepatitis , liver disease , population , hepatitis , adverse effect , hepatitis c , viral load , hepatitis b , disease , immunology , human immunodeficiency virus (hiv) , environmental health

Essential phospholipids (EPL) are used as adjuvant treatment in people with fatty liver disease and other chronic liver diseases. A new formulation of EPL paste was developed to improve patient compliance. The study was aimed to assess the safety, patient-reported outcomes, and impact on compliance of the new EPL paste formulation in patients with non-alcoholic fatty liver disease (NAFLD) or viral hepatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research